XORTX Therapeutics Inc. Common Shares (XRTX)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, XORTX traded at $1.68 with a market capitalization of only $4.1 million. This is a clinical-stage pharmaceutical company with a pipeline: XRx-026 in Phase III for gout, and XRx-008 and XRx-101 in Phase II. That is not a business with a moat; it is a collection of binary scientific options. Graham would ask for demonstrated earning power and a margin of safety. Instead, FairStock calculations from the supplied data show a negative P/E of -0.65, price-to-book of 1.12, ROE of -99.24%, ROCE of -29.85%, and a free cash flow yield of -127.8%. Free cash flow is -$5.3 million over the trailing twelve months, meaning the company is burning cash at a rate far larger than its market value. The balance sheet has low financial leverage, with D/E of 0.01, but that does not remove the need for future financing. Financial strength scores are poor: Piotroski F-Score 1/9 and Altman Z-Score -1.97. The Lynch category is none because there are only 0 years of filed results versus the 3 required. Revenue growth is not available, so growth must be judged by pipeline progress. The 52-week range of $1.36 to $7.05 shows how volatile the shares have been. Without earnings, book value and trial milestones dominate. I would call this speculative, not investment-grade on current facts. Any value depends on trial success and financing terms, not on present business quality.

In plain English: XORTX Therapeutics is a small drug development company working on experimental treatments for gout and kidney-related diseases. The supplied numbers show it is losing money and burning cash, so the business looks weak today. Because it has no profits and is spending cash, the $1.68 price looks expensive relative to the current business, though the value really depends on future trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer